Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI). CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after PCI. After clinical genotyping, each in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JACC. Cardiovascular interventions Ročník 11; číslo 2; s. 181
Hlavní autoři: Cavallari, Larisa H, Lee, Craig R, Beitelshees, Amber L, Cooper-DeHoff, Rhonda M, Duarte, Julio D, Voora, Deepak, Kimmel, Stephen E, McDonough, Caitrin W, Gong, Yan, Dave, Chintan V, Pratt, Victoria M, Alestock, Tameka D, Anderson, R David, Alsip, Jorge, Ardati, Amer K, Brott, Brigitta C, Brown, Lawrence, Chumnumwat, Supatat, Clare-Salzler, Michael J, Coons, James C, Denny, Joshua C, Dillon, Chrisly, Elsey, Amanda R, Hamadeh, Issam S, Harada, Shuko, Hillegass, William B, Hines, Lindsay, Horenstein, Richard B, Howell, Lucius A, Jeng, Linda J B, Kelemen, Mark D, Lee, Yee Ming, Magvanjav, Oyunbileg, Montasser, May, Nelson, David R, Nutescu, Edith A, Nwaba, Devon C, Pakyz, Ruth E, Palmer, Kathleen, Peterson, Josh F, Pollin, Toni I, Quinn, Alison H, Robinson, Shawn W, Schub, Jamie, Skaar, Todd C, Smith, D Max, Sriramoju, Vindhya B, Starostik, Petr, Stys, Tomasz P, Stevenson, James M, Varunok, Nicholas, Vesely, Mark R, Wake, Dyson T, Weck, Karen E, Weitzel, Kristin W, Wilke, Russell A, Willig, James, Zhao, Richard Y, Kreutz, Rolf P, Stouffer, George A, Empey, Philip E, Limdi, Nita A, Shuldiner, Alan R, Winterstein, Almut G, Johnson, Julie A
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 22.01.2018
Témata:
ISSN:1876-7605, 1876-7605
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI). CYP2C19 loss-of-function alleles impair clopidogrel effectiveness after PCI. After clinical genotyping, each institution recommended alternative antiplatelet therapy (prasugrel, ticagrelor) in PCI patients with a loss-of-function allele. Major adverse cardiovascular events (defined as myocardial infarction, stroke, or death) within 12 months of PCI were compared between patients with a loss-of-function allele prescribed clopidogrel versus alternative therapy. Risk was also compared between patients without a loss-of-function allele and loss-of-function allele carriers prescribed alternative therapy. Cox regression was performed, adjusting for group differences with inverse probability of treatment weights. Among 1,815 patients, 572 (31.5%) had a loss-of-function allele. The risk for major adverse cardiovascular events was significantly higher in patients with a loss-of-function allele prescribed clopidogrel versus alternative therapy (23.4 vs. 8.7 per 100 patient-years; adjusted hazard ratio: 2.26; 95% confidence interval: 1.18 to 4.32; p = 0.013). Similar results were observed among 1,210 patients with acute coronary syndromes at the time of PCI (adjusted hazard ratio: 2.87; 95% confidence interval: 1.35 to 6.09; p = 0.013). There was no difference in major adverse cardiovascular events between patients without a loss-of-function allele and loss-of-function allele carriers prescribed alternative therapy (adjusted hazard ratio: 1.14; 95% confidence interval: 0.69 to 1.88; p = 0.60). These data from real-world observations demonstrate a higher risk for cardiovascular events in patients with a CYP2C19 loss-of-function allele if clopidogrel versus alternative therapy is prescribed. A future randomized study of genotype-guided antiplatelet therapy may be of value.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1876-7605
1876-7605
DOI:10.1016/j.jcin.2017.07.022